How does health connect us all?

AstraZeneca 2010 In Brief

AstraZeneca 2010 In Brief A

data suggests that up to 15% of patients die within one year of their cardiovascular event. involving 18. and doctors. The clinical development for Brilinta/Brilique included the PLATO study. AstraZeneca has been at the forefront of R&D in cardiovascular diseases. For more than half a century. Brilinta/Brilique was discovered at our laboratories in the UK and represents another example of our commitment to developing and delivering innovative medicines that make a meaningful difference to patient health. one of the largest clinical trials we have ever undertaken. Health is something that connects us all In our mission to make a meaningful difference to the world’s health.Acute coronary syndromes – or ACS – is a term used to describe sudden chest pain and other symptoms caused by an insufficient blood supply to the heart. Despite the availability of current treatment options. Brilinta/Brilique (ticagrelor tablets) is an oral antiplatelet treatment we have developed for ACS. The overall PLATO results demonstrated the superiority of ticagrelor in reducing heart attacks and cardiovascular death in patients with ACS.5 million occurrences in the developed world each year. Through our activities we touch a great number of people’s lives and we are acutely conscious of our responsibility to patients and society in general. we work closely with governments and regulators. The data has provided the basis for regulatory filings annualreport2010 AstraZeneca 2010 In Brief 1 .com/ annualreport2010 Who can help me survive a heart attack? B AstraZeneca 2010 In Brief You will find more detail and further information on all the case studies featured in this document on our website. astrazeneca. our partners in industry and academia. those who pay for healthcare. astrazeneca. PLATO was designed to reflect current clinical management of ACS patients and to establish whether Brilinta/Brilique could improve cardiovascular outcomes beyond those afforded by clopidogrel (Plavix™/Iscover™). They are the most common manifestation of coronary heart disease (CHD) with over 2.624 patients in 43 countries.

including Sweden. a respiratory infection in infants Neuroscience Seroquel IR for schizophrenia and bipolar disorder Seroquel XR Oncology Over 80 major externalisation transactions completed over the past three years for schizophrenia.2 billion in our R&D organisation in 2010 for RSV. Mexico. heart failure and angina Gastrointestinal AstraZeneca is a focused.176 million in Established Rest of World markets and $5.000 employees worldwide Active in over 100 countries Our mission is to make a meaningful difference to patient health through great medicines We are committed to acting responsibly and to the sustainable development of our business 10 medicines with sales of over $1 billion in 2010 Crestor for managing cholesterol levels Seloken/Toprol-XL Atacand Nexium for acid reflux for hypertension and heart failure hypertension.198 million in Emerging Markets Combining our disease area expertise with country-specific knowledge helps us to market and sell medicines that best meet local needs Of our 61. we had sales of $13.000 employees worldwide. we provide a culture in which they can feel appreciated. prescription-based biopharmaceutical business $4. we want to be valued for the contribution our medicines make to society and trusted for the way in which we do business We recognise the value of collaborative work and so continually seek to develop new ways of working with others who complement our existing skills.700 people work in our R&D organisation and we have 14 principal R&D centres in eight countries. Brazil and Russia In 2010. society and our shareholders Arimidex Zoladex for breast cancer for prostate and breast cancer 46% of sales and marketing workforce based in Emerging Markets compared with 16% in 2002 Respiratory & Inflammation Symbicort for asthma and chronic obstructive pulmonary disease 23 Supply and Manufacturing sites AstraZeneca 2010 In Brief 3 2 AstraZeneca 2010 In Brief .000 10 100 Focus on six areas of healthcare 61. with a growing presence in emerging markets such as China. bipolar disorder and major depressive disorder Our mission requires us to do things in the right way – to behave in accordance with our values and act with integrity We believe that our approach delivers lasting value for patients. we provide medicines for some of the world’s most serious illnesses For the people who pay for healthcare.727 million in the US. we aim to deliver value through our continued focus on innovation and running our business efficiently For the wider community. 45.168 million in Western Europe.9% in Asia. Neuroscience. develop and commercialise prescription medicines for six important areas of healthcare: Cardiovascular. enhance our internal innovation or bring extra value to what we do Where we work We have a global reach but local knowledge. Oncology and Respiratory & Inflammation We have a broad range of medicines that includes established treatments for many serious illnesses such as our antibiotic. 30. Merrem/Meronem and Losec/Prilosec for acid related diseases We use our scientific and commercial skills to develop a pipeline of innovative new medicines to meet medical need We had 10 medicines with sales of more than $1 billion each in 2010 Cardiovascular How we work Our activities touch many people’s lives and we are committed to working in a spirit of collaboration to achieve our goal of better health for patients For patients and doctors.6% are in Europe.Who we are What we do We discover. innovation-driven. $9. we work to make sure that our medicines offer value for money For our employees. Infection. the US and the UK We have 9.5% in the Americas and 23. Gastrointestinal. Africa and Australasia Around 15. $5. energised and rewarded for their contribution For our shareholders.2bn 80 46% 23 Infection Synagis Core investment of $4. global. being active in over 100 countries. integrated.300 employees at 23 Supply and Manufacturing sites in 16 countries 6 61.

19 Dividend information Dividend for 2010 $ Pence SEK Payment date First interim dividend Second interim dividend Total 0. resulting in annual benefits of $2.217 25.977 – 2.20 5.10 6.680 11.4bn Revenue in the US fell 7%. a 16% increase The first phase of the restructuring programme is now complete.601 Operational overview Core operating profit $m (unchanged) 2010 2009 2008 10. enables ‘real world’ studies of health outcomes > Portfolio of more than 100 generic products being licensed across 30 Emerging Markets for marketing under our brand > Crestor substance patent upheld in the US courts > Ranked in the top 8% in the sector in the Dow Jones Sustainability World and European Indexes > Reviewed and revised Responsible Business Plan to align it with strategic business priorities > Additional ways of reporting sales and marketing performance introduced to support increased transparency > Improvement in senior leader communications with employees but slight decline in employee engagement All growth rates are at CER 92 projects in clinical development.621 92 > Single R&D organisation in place.Our year in brief Sales $m (unchanged) 2010 2009 2008 33.99 17. while revenue in Rest of World rose by 7% Annual Crestor and Seroquel sales exceeded $5 billion each Revenue in Emerging Markets grew to over $5.85 2.739 Reported operating profit $m (-1%) 2010 2009 2008 9.1bn Net share repurchases totalled $2.110 million.804 31.4 billion Distributions to shareholders $m 2010 2009 2008 Dividends Share repurchases 1 3.603 13. also entered Phase III development > Agreement with HealthCore. were $2. global organisation structure and governance framework > Vimovo approved in the US and the EU.543 Reported gross margin $m (-1%) 2010 2009 2008 26. 34 withdrawn during the year Core gross margin $m (-1%) 2010 2009 2008 27. decisions made in December to discontinue development of motavizumab and Certriad > Completed a deal with Rigel for the Phase III development of fostamatinib (for rheumatoid arthritis).11 13 September 2010 14 March 2011 7% $5bn $5.1 billion in 2010 4 AstraZeneca 2010 In Brief AstraZeneca 2010 In Brief 5 .9 116.408 Core earnings per Ordinary Share $ (+5%) 2010 2009 2008 5.7 161.60 5. which maintains the largest commercially insured population data environment in the US.1 billion. $2.003 Reported basic earnings per Ordinary Share $ (+7%) 2010 2009 2008 4.958 13.361 2.1bn $2. Kombiglyze™ XR (Onglyza™/metformin combination) approved in the US. our neuroscience collaboration with Targacept.742 10.144 11.024 27. including 9 in Phase III or under regulatory review.70 1.32 Net cash flow from operating activities $m 2010 2009 2008 8.880 27.6041 2.269 32.494 11.55 44.029 25.739 610 Share repurchases in 2010.71 6. Brilique approved in the EU with Complete Response Letter received for Brilinta in the US. and TC-5214.6 5. including new leadership team. net of proceeds from the issue of share capital equal to $494 million.12 11.

It is estimated that by 2025 there will be an additional 100 million sufferers. especially among children. . Research shows that with the right treatment nearly all asthma patients can achieve and maintain good asthma control. Symbicort pMDI (pressurised metered-dose inhaler) is approved in the US for the treatment of asthma in patients 12 years of age and older. our Symbicort Turbuhaler maintenance and reliever therapy (SMART) combines both regular maintenance and as-needed reliever therapies. It is the only asthma treatment regime to do so and allows patients to control daily symptoms and reduce the severity and number of asthma attacks using a single inhaler. it can be treated effectively. It gives asthma patients what they want in daily symptom control and also gives them what they need in the longer term – improved asthma management. enabling them to live full and active lives. It is one of the most common chronic diseases and its prevalence is increasing every year. Outside the US. Although asthma cannot be cured. Our Symbicort medicine provides important improvement in the health of many patients with asthma.How can I help manage my asthma? Approximately 300 million people worldwide suffer from asthma.

AstraZeneca is sponsoring a three-year programme. We are also supporting the Chinese Ministry of Health in improving patient health with an innovative programme to increase the capacity of community healthcare services by strengthening the training of general practitioners. nearly 900 million people live outside big cities and the Chinese government is investing $125 billion between 2009 and 2011 to support healthcare reform by expanding basic healthcare insurance and upgrading community and rural hospitals. We have plans to build a sustainable business in this broader market.What is being done to improve health in China? AstraZeneca is one of the country’s fastest growing multinational pharmaceutical companies. At the same time.000 community general practitioners so that they can better treat some common chronic diseases. It will help train some 30. . In collaboration with the China Medical Association. which will be providing the training. We are investing to improve our sales capabilities in these and in a further 100 large cities. At present. most of our business comes from big hospitals in 200 of the largest cities that have a population of more than one million.

Working in collaboration with the Ugandan government in the districts of Luwero and Kiboga in central Uganda. the two diseases are a deadly combination.TB is the leading cause of death in people living with HIV. The diseases are linked but Ugandans with TB/ HIV. 108 health workers have been trained in drug logistics management to help prevent shortages. a study of drug logistics management revealed significant knowledge gaps and out of stock supply problems. Our partnership with the African Medical and Research Foundation (AMREF) is focused on developing a model for the integrated management of TB. Who is improving my healthcare? . Subsequently. In Uganda. HIV/AIDS and malaria that provides a framework for effective and efficient healthcare at local and national levels. malaria and other conditions have to attend separate health services for treatment.300 people trained in health promotion in their local communities. Progress to date includes the completion and handover to local district management teams of four new laboratories and the establishment of 328 village health teams with over 1. Together. In addition. the partnership has focused on increasing laboratory diagnostic capacity and improving community-based healthcare management. which causes more illness and death than any other single disease. there is the added burden of malaria.

See the 2010 Reconciliation of Reported results to Core results table on page 82 of the Annual Report for a reconciliation of Reported to Core performance. including websites. the ‘Group’. such as charges and provisions related to our global restructuring programmes. AstraZeneca’s determination of non-GAAP measures together with our presentation of them within our financial information may differ from similarly titled non-GAAP measures of other companies. we can be more effective if we can identify the patients likely to benefit most from particular medicines. references to days and/or months in this document are references to days and/or months in 2010. it should not be read as a substitute for the Annual Report itself. astrazeneca. Defined terms Unless otherwise defined in this document. We worked with a variety of healthcare professionals (HCPs) to improve education and best practice in EGFR testing. A reconciliation of the Reported results adjusted for the impact of currency movements is provided in the 2010 Reported operating profit table on page 82 of the Annual Report. including hedging). AstraZeneca 2010 In Brief 13 How do I find a cancer treatment that’s right for me? . it worked well on some patients and subsequent analysis of data from clinical studies showed that it was superior to conventional chemotherapy in 1st line treatment of lung cancer patients who had a mutation of the EGFR gene. extracted from the Annual Report and Form 20-F Information 2010 (Annual Report) for AstraZeneca PLC (the Company). Statement of dates Except as otherwise stated. Workshops involving pathologists. These measures are adjusted to exclude certain significant items. AstraZeneca. Iressa is pioneering. Accordingly. As the first personalised medicine in lung cancer. These were complemented by digital activities. > Constant exchange rate (CER) growth rates. defined terms used in this document shall have the meaning given to them in the Annual Report. The Company. Website A copy of the Annual Report is available on our website. Inclusion of reported performance. These are also non-GAAP measures. the amortisation and impairment of the significant intangibles relating to our current and future exit arrangements with Merck in the US and other specified items. amortisation and impairment of the significant intangibles relating to the acquisition of MedImmune in 2007. Reported performance takes into account all the factors (including those which we cannot influence. These are non-GAAP measures because unlike Reported performance they cannot be derived directly from the information in the Group’s Financial Statements.In a world where there is increasing pressure on healthcare budgets. not just for the benefits it offers patients. Consequently. it should only be read in conjunction with the Annual Report. Identifying the right treatment for the right patient at the right time and to embed it as part of routine clinical practice was the major challenge for Iressa. > Core financial measures. oncologists and respiratory physicians were run around the world. This information is provided solely for the convenience of current and future members of the Company and is only intended to introduce the information contained in the Annual Report. Directors and officers shall not be liable for the consequence of any action taken solely in reliance on the information contained in this document. to promote best practice and facilitate routine diagnostic testing. Throughout this document. its subsidiaries. The Company and its subsidiaries are variously referred to herein as ‘AstraZeneca’. At one stage Iressa had its submissions withdrawn because its benefits failed to reach statistical significance in the overall population. These measures remove the effects of currency movements (by retranslating the current year’s performance at the previous year’s exchange rates and adjusting for other exchange effects. and even iPhone applications. Further information AstraZeneca 2010 In Brief This document contains information. ‘we’. growth rates are expressed at CER unless otherwise It is not intended to satisfy any statutory and/or regulatory requirements in the UK or elsewhere. e-learning. However. the AstraZeneca logotype and the AstraZeneca symbol are all trade marks of the Group. but for the way in which it has brought together different groups of HCPs and changed the way patients are tested and treated as part of routine clinical practice. It is also available by request from the Company Secretary. We have experience of this personalised healthcare approach with our lung cancer therapy Iressa. ‘us’ and ‘our’. core financial measures and constant exchange rate growth rates The following measures are referred to in this document: > Reported performance. principally currency exchange rates) that have affected the results of our business as reflected in our Group Financial Statements prepared in accordance with International Financial Reporting Standards as adopted by the EU and as issued by the International Accounting Standards Board. Trade marks Trade marks of the Group appear throughout this document in italics. including financial information.

The forward-looking statements reflect knowledge and information available at the date of the preparation of this document and the Company undertakes no obligation to update these forward-looking statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements. to utilise the ‘safe harbour’ provisions of the US Private Securities Litigation Reform Act of 1995 and the UK Companies Act 2006. those factors identified in the Principal risks and uncertainties section from page 96 of the Annual Report. we are providing the following cautionary statement: This document contains certain forwardlooking statements with respect to the operations. agents and advisors do not accept or assume responsibility to any other person to whom this document is shown or into whose hands it may come and any such responsibility or liability is expressly disclaimed. including information relating to risks and uncertainties. ‘intends’ and similar expressions in such statements. ‘believes’. The Company and its Directors. performance and financial condition of the Group. Nothing in this document or in the Annual Report should be construed as a profit forecast. Although we believe that the forward-looking statements in this document are based on reasonable assumptions. In order. . Forward-looking statements are statements relating to the future which are based on information available at the time such statements are made. ‘expects’. certain of which are beyond our control. the matters discussed in the forward-looking statements may be influenced by factors that could cause actual outcomes and results to be materially different from those expressed or implied by these statements. among other things.Registered office and corporate headquarters AstraZeneca PLC 2 Kingdom Street London W2 6BD UK Tel: +44 (0)20 7604 8000 Fax: +44 (0)20 7604 8151 Cautionary statement regarding forward-looking statements The purpose of this document is to provide information to the members of the Company. employees. among other things. We identify the forward-looking statements by using the words ‘anticipates’. include.

Sign up to vote on this title
UsefulNot useful